Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$10.95
-0.9%
$10.26
$8.37
$13.14
N/A0.26186,023 shs56,170 shs
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$24.50
$26.54
$22.56
$28.92
$5.44B0.57159 shsN/A
Merck KGaA stock logo
MKKGY
Merck KGaA
$25.42
+0.6%
$25.85
$24.32
$39.17
$16.43B0.91142,122 shs94,206 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$23.70
-2.9%
$25.46
$11.76
$36.91
$17.61B-1.063.62 million shs2.54 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
+0.82%-2.30%+9.73%+12.81%-11.10%
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
0.00%+0.57%-12.37%-11.65%-5.62%
Merck KGaA stock logo
MKKGY
Merck KGaA
+0.02%-2.24%-3.42%-3.87%-34.44%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-1.57%-6.11%-8.68%+30.87%+86.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Merck KGaA stock logo
MKKGY
Merck KGaA
2.552 of 5 stars
0.03.02.50.01.10.03.1
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.2482 of 5 stars
4.31.00.00.01.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00
N/AN/AN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
3.00
BuyN/AN/A
Merck KGaA stock logo
MKKGY
Merck KGaA
2.33
HoldN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.63
Moderate Buy$33.3140.01% Upside

Current Analyst Ratings Breakdown

Latest HKMPF, ALPMY, SMMT, and MKKGY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $50.00
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$21.00
8/19/2025
Merck KGaA stock logo
MKKGY
Merck KGaA
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$40.00
8/18/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$21.00
8/15/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
8/14/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/12/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $34.00
8/8/2025
Merck KGaA stock logo
MKKGY
Merck KGaA
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$12.56BN/A$1.80 per share6.09$5.52 per shareN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$3.13B1.74$2.23 per share10.98$11.50 per share2.13
Merck KGaA stock logo
MKKGY
Merck KGaA
$22.57B0.73$8.21 per share3.10$50.22 per share0.51
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K25,246.29N/AN/A$0.35 per share67.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$334.93M$0.3036.5516.13N/A4.34%19.76%8.75%10/29/2025 (Estimated)
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$359MN/A0.00N/AN/AN/AN/AN/A
Merck KGaA stock logo
MKKGY
Merck KGaA
$3.00B$2.3810.6912.413.1113.49%9.81%5.73%11/13/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)

Latest HKMPF, ALPMY, SMMT, and MKKGY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.76-$0.66-$0.76N/AN/A
8/7/2025Q2 2025
Merck KGaA stock logo
MKKGY
Merck KGaA
$0.51$0.57+$0.06$0.57$5.34 billion$6.11 billion
7/30/2025Q1 2026
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.1356$0.40+$0.2644$0.26$3.20 billion$3.41 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.353.19%N/A116.67%N/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$0.722.94%N/AN/AN/A
Merck KGaA stock logo
MKKGY
Merck KGaA
$0.341.34%N/A14.29%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.37
1.13
0.85
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
0.33
1.24
0.72
Merck KGaA stock logo
MKKGY
Merck KGaA
0.23
1.31
0.83
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.13
5.13

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
N/A
Merck KGaA stock logo
MKKGY
Merck KGaA
0.10%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
N/A
Merck KGaA stock logo
MKKGY
Merck KGaA
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,754N/AN/ANot Optionable
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
9,500221.89 millionN/ANot Optionable
Merck KGaA stock logo
MKKGY
Merck KGaA
62,557646.21 millionN/ANot Optionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.85 million112.17 millionOptionable

Recent News About These Companies

This Is What Whales Are Betting On Summit Therapeutics
Summit Therapeutics (NASDAQ:SMMT) Cut to "Sell" at Wall Street Zen
SMMT FY2025 EPS Estimate Reduced by Cantor Fitzgerald
3 Fantastic Growth Stocks to Buy in August

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$10.95 -0.10 (-0.90%)
As of 03:58 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Hikma Pharmaceuticals stock logo

Hikma Pharmaceuticals OTCMKTS:HKMPF

$24.50 0.00 (0.00%)
As of 08/28/2025

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Merck KGaA stock logo

Merck KGaA OTCMKTS:MKKGY

$25.42 +0.16 (+0.61%)
As of 03:59 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$23.70 -0.72 (-2.95%)
Closing price 04:00 PM Eastern
Extended Trading
$23.81 +0.11 (+0.46%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.